Statistical Analysis Plan: IT001-302
Total Page:16
File Type:pdf, Size:1020Kb
Statistical Analysis Plan: IT001-302 Study Title: A prospective, Phase 3, randomized, multi-center, double-blind, double dummy study of the efficacy, tolerability and safety of intravenous sulopenem followed by oral sulopenem-etzadroxil with probenecid versus intravenous ertapenem followed by oral ciprofloxacin or amoxicillin-clavulanate for treatment of complicated urinary tract infections in adults. Study Number: IT001-302 Study Phase: Phase 3 Product Name: Sulopenem (CP-70,429), Sulopenem-etzadroxil (PF-03709270)/Probenecid Indication: Complicated urinary tract infection Study Statistician: Michael Zelasky Study Clinician: Steven I. Aronin, M.D. Sponsor: Iterum Therapeutics International Limited 20 Research Parkway, Suite A Old Saybrook, CT 06475 Final SAP Date: September 25, 2019 Revised SAP Date: February 11, 2020 Protocol Version: January 16, 2020 Confidentiality Statement This document is strictly confidential. It was developed by Iterum Therapeutics US Limited should not be disclosed to a third party, with the exception of regulatory agencies and study audit personnel. Reproduction, modification or adaptation, in part or in total, is strictly forbidden without prior written approval by Iterum Therapeutics US Limited Digitally signed by Anita F Das DN: cn=Anita F Das, o, ou, [email protected]. Anita F Das com, c=US Date: 2020.02.12 12:57:12 -08'00' Sulopenem IV; Sulopenem etzadroxil Iterum Therapeutics Statistical Analysis Plan: IT001-302 11 February 2020 TABLE OF CONTENTS TABLE OF CONTENTS............................................................................................................ 3 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS............................................. 5 1 INTRODUCTION............................................................................................................. 7 2 STUDY DESIGN............................................................................................................... 7 3 STUDY OBJECTIVES..................................................................................................... 7 3.1 Primary Objective ................................................................................................. 7 3.2 Secondary Objectives ........................................................................................... 7 4 DEFINITION OF ANALYSIS POPULATIONS........................................................... 8 4.1 Intent-to-Treat (ITT)............................................................................................ 8 4.2 Modified Intent-to-Treat (MITT) ....................................................................... 8 4.3 Microbiological Modified Intent-to-Treat (micro-MITT or m-MITT)......... 8 4.4 Clinical Evaluable (CE) ......................................................................................... 8 4.5 Microbiological Evaluable (ME)......................................................................... 9 4.6 Safety ....................................................................................................................... 9 4.7 Determination of Inclusion in Analysis Populations................................... 10 5 DEFINITION OF OUTCOMES ................................................................................... 10 5.1 Overall Response................................................................................................... 10 5.2 Microbiologic Response........................................................................................ 11 5.2.1 Baseline Pathogens................................................................................................ 11 5.2.2 Post-Baseline Pathogens ....................................................................................... 13 5.3 Patient-Determined Clinical Response (Clinical Response) ............................. 14 5.4 Investigator-Determined Clinical Response:...................................................... 15 5.5 Patient Symptom Assessment Questionnaire (PSAQ)....................................... 15 5.6 Other Signs and Symptoms.................................................................................. 16 5.7 Safety Outcome Measures.................................................................................. 16 6 STATISTICAL METHODS .......................................................................................... 16 6.1 Sample Size........................................................................................................... 16 6.2 Randomization ...................................................................................................... 17 6.3 Visit Windows........................................................................................................ 17 6.4 Microbiology Data ................................................................................................ 17 6.5 Handling of Missing Data..................................................................................... 18 6.6 Comments on Statistical Analysis........................................................................ 20 7 STATISTICAL ANALYSES ......................................................................................... 21 Confidential 3 Sulopenem IV; Sulopenem etzadroxil Iterum Therapeutics Statistical Analysis Plan: IT001-302 11 February 2020 7.1 Patient Disposition ................................................................................................ 21 7.2 Demographics and Baseline Characteristics ...................................................... 21 7.2.1 Baseline Microbiology.................................................................................. 22 7.3 Prior and Concomitant Medications................................................................... 22 7.4 Study Drug Exposure ........................................................................................... 23 7.5 Efficacy Analyses .................................................................................................. 23 7.5.1 Primary Efficacy Analysis.................................................................................... 23 7.5.2 Additional Analyses of the Primary Efficacy Outcome..................................... 24 7.5.3 Secondary Efficacy Analysis................................................................................ 26 7.5.4 Additional Efficacy Analyses ............................................................................... 26 7.6 Interim Analysis.................................................................................................... 31 7.7 Safety Analyses...................................................................................................... 32 7.7.1 Adverse Events...................................................................................................... 32 7.7.1.1 Diarrhea Episodes................................................................................................. 32 7.7.2 Laboratory Values ................................................................................................ 33 7.7.3 Physical Examinations.......................................................................................... 34 7.7.4 Vital Signs.............................................................................................................. 34 7.8 Protocol Deviations ............................................................................................... 35 8 DIFFERENCES WITH ANALYSES SPECIFIED IN THE PROTOCOL............... 36 9 REFERENCES................................................................................................................ 37 Appendix A: Schedule of Activities ............................................................................. 38 Appendix B: Criteria for Safety Values of Potential Clinical Concern........................ 40 Appendix C: Method for Determination of Creatinine Clearance................................ 41 Appendix D: Microbiology Rules for Determination of Final Pathogen ..................... 42 Confidential 4 Sulopenem IV; Sulopenem etzadroxil Iterum Therapeutics Statistical Analysis Plan: IT001-302 11 February 2020 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS AE Adverse Event BMI Body Mass Index CE Clinical Evaluable CFU Colony Forming Unit CI Confidence Interval CRF Case Report Form CSR Clinical Study Report cUTI Complicated Urinary Tract Infection EOT End of Treatment Visit ESBL Extended-6SHFWUXPȕ-Lactamases FDA Food and Drug Administration FV Final Visit GCP Good Clinical Practice IA Interim Analysis ITT Intent-to-Treat IWRS Interactive Web Response System m-MITT Microbiological Modified Intent-to-Treat ME Microbiological Evaluable MedDRA Medical Dictionary for Regulatory Activities MG Milligram MIC Minimum Inhibitory Concentration micro-MITT Microbiological Modified Intent-to-Treat MITT Modified Intent-to-Treat NDA New Drug Application Confidential 5 Sulopenem IV; Sulopenem etzadroxil Iterum Therapeutics Statistical Analysis Plan: IT001-302 11 February 2020 PD Pharmacodynamic PK Pharmacokinetic PO Orally PSAQ Patient Symptom Assessment Questionnaire SAE serious adverse event SAP Statistical Analysis Plan SD standard deviation SE standard error Tfree>MIC Time of free concentration above MIC TOC Test of Cure Visit WHODRUG World Health Organization (WHO) Drug Dictionary Confidential 6 Sulopenem IV; Sulopenem etzadroxil Iterum Therapeutics Statistical Analysis Plan: IT001-302 11 February 2020 1 INTRODUCTION